Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Jan 12;11(1):e006136. doi: 10.1136/jitc-2022-006136

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.

PMC Copyright notice

Plasma protein biomarkers IP-10, IP-10/IL-8 ratio, IL8, and IL-6 showed differences in the clinical benefit metastatic colorectal cancer (mCRC) participants (PR+SD) compared with the non-clinical benefit mCRC participants (PD+NE). IP-10 levels significantly rose by D22 and D25 in the benefit group but not the non-benefit group (A). The IP-10/IL-8 ratio was higher overall in the benefit group and on D25 (B). IL-8 was lower overall in the benefit participants compared with the non-benefit participants but there were no significant differences during treatment (C). IL-6 was higher overall in the benefit group but there were no significant differences during treatment (D). Comparisons performed with ANOVA (*p<0.05, **p<0.01). ANOVA, analysis of variance; PR, partial response; SD, stable diseas.